{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:22:07Z","timestamp":1789204927834,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.ctrv.2015.09.002","type":"journal-article","created":{"date-parts":[[2015,9,12]],"date-time":"2015-09-12T18:46:33Z","timestamp":1442083593000},"page":"793-797","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Mechanisms of anorexia\u2013cachexia syndrome and rational for treatment with selective ghrelin receptor agonist"],"prefix":"10.1016","volume":"41","author":[{"given":"Angela","family":"Esposito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Criscitiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Gelao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Pravettoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Minchella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Di Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Liuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Milani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Massaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2015.09.002_b0005","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1152\/physrev.00016.2008","article-title":"Mechanisms of cancer cachexia","volume":"89","author":"Tisdale","year":"2009","journal-title":"Physiol Rev"},{"key":"10.1016\/j.ctrv.2015.09.002_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13539-010-0002-6","article-title":"Cachexia as a major underestimated and unmet medical need: facts and numbers","volume":"1","author":"von Haehling","year":"2010","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ctrv.2015.09.002_b0015","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jpainsymman.2006.10.015","article-title":"Symptom prevalence in patients with incurable cancer: a systematic review","volume":"34","author":"Teunissen","year":"2007","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.ctrv.2015.09.002_b0020","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0959-8049(97)10090-9","article-title":"Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?","volume":"34","author":"Andreyev","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2015.09.002_b0025","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0149-2918(05)80001-3","article-title":"Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group","volume":"69","author":"Dewys","year":"1980","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.ctrv.2015.09.002_b0030","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2015.09.002_b0035","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1124\/pr.57.4.1","article-title":"International Union of Pharmacology. LVI. Ghrelin receptor nomenclature, distribution, and function","volume":"57","author":"Davenport","year":"2005","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.ctrv.2015.09.002_b0040","first-page":"80","article-title":"Endocrine and metabolic activities of a recently isolated peptide hormone ghrelin, an endogenous ligand of the growth hormone secretagogue receptor","volume":"38","author":"Jarkovska","year":"2004","journal-title":"Endocr Regul"},{"issue":"2","key":"10.1016\/j.ctrv.2015.09.002_b0045","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/gast.2001.22158","article-title":"Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin","volume":"120","author":"Asakawa","year":"2001","journal-title":"Gastroenterology"},{"issue":"19","key":"10.1016\/j.ctrv.2015.09.002_b0050","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1002\/cncr.27430","article-title":"Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: prospective, randomized, placebo-controlled Phase 2 study","volume":"118","author":"Hiura","year":"2012","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2015.09.002_b0055","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0304-3940(03)00789-4","article-title":"Centrally administered ghrelin suppresses sympathetic nerve activity in brown adipose tissue of rats","volume":"349","author":"Yasuda","year":"2003","journal-title":"Neurosci Lett"},{"issue":"1","key":"10.1016\/j.ctrv.2015.09.002_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/cyto.2001.0898","article-title":"Brain cytokine production and action in anorexia and cachexia","volume":"15","author":"Plata-Salaman","year":"2001","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.ctrv.2015.09.002_b0065","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1172\/JCI200421134","article-title":"Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells","volume":"114","author":"Dixit","year":"2004","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.ctrv.2015.09.002_b0070","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0896-6273(03)00063-1","article-title":"The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis","volume":"37","author":"Cowley","year":"2003","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/j.ctrv.2015.09.002_b0075","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ghir.2008.12.003","article-title":"Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers","volume":"19","author":"Garcia","year":"2009","journal-title":"Growth Horm IGF Res"},{"issue":"2","key":"10.1016\/j.ctrv.2015.09.002_b0080","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/jcsm.12023","article-title":"Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved","volume":"6","author":"Chen","year":"2015","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ctrv.2015.09.002_b0085","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.peptides.2011.01.021","article-title":"The role of C-terminal part of ghrelin in pharmacokinetic profile and biological activity in rats","volume":"32","author":"Morozumi","year":"2011","journal-title":"Peptides"},{"key":"10.1016\/j.ctrv.2015.09.002_b0090","first-page":"593","article-title":"Biologic activity of RC-1291, a novel oral ghrelin mimetic for cancer anorexia\/cachexia: results from a Phase I randomized, double-blind, placebo-controlled trial in healthy volunteers","volume":"14","author":"Kumor","year":"2006","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ctrv.2015.09.002_b0095","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00520-012-1500-1","article-title":"Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study","volume":"21","author":"Garcia","year":"2013","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2015.09.002_b0100","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s13539-014-0159-5","article-title":"Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia\u2013cachexia syndrome: preclinical profile","volume":"5","author":"Pietra","year":"2014","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ctrv.2015.09.002_b0105","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2217\/fon.14.14","article-title":"Anamorelin hydrochloride in the treatment of cancer anorexia\u2013cachexia syndrome","volume":"10","author":"Currow","year":"2014","journal-title":"Future Oncol"},{"key":"10.1016\/j.ctrv.2015.09.002_b0110","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.12-5-594","article-title":"Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a Phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers","volume":"12","author":"Garcia","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2015.09.002_b0115","first-page":"583","article-title":"Biologic activity of RC-1291, a novel oral ghrelin mimetic for cancer anorexia\/cachexia: results from a Phase I randomized, double-blind, placebo controlled trial in healthy volunteers","volume":"14","author":"Kumor","year":"2006","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ctrv.2015.09.002_b0120","first-page":"295","article-title":"Efficacy and safety results from a Phase II study of anamorelin HCl, a ghrelin receptor agonist, in NSCLC patients","volume":"4","author":"Temel","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"1","key":"10.1016\/j.ctrv.2015.09.002_b0125","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S1470-2045(14)71154-4","article-title":"Anamorelin for patients with cancer cachexia: an integrated analysis of two Phase 2, randomised, placebo-controlled, double-blind trials","volume":"16","author":"Garcia","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2015.09.002_b0130","unstructured":"Temel J, Currow D, Fearon K, et al. Anamorelin for the treatment of cancer anorexia\u2013cachexia in NSCLC: results from the Phase 3 studies ROMANA 1 and 2. In: ESMO 2014 Congress. Abstract 1483O-PR. Presented September 27, 2014."},{"key":"10.1016\/j.ctrv.2015.09.002_b0135","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.e20715","article-title":"A safety extension study of anamorelin in advanced non-small cell lung cancer patients with cachexia: ROMANA 3","volume":"33","author":"Currow","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2015.09.002_b0140","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1677\/joe.0.1650139","article-title":"Specific binding sites for synthetic growth hormone secretagogues in non-tumoral and neoplastic human thyroid tissue","volume":"165","author":"Cassoni","year":"2000","journal-title":"J Endocrinol"},{"issue":"4","key":"10.1016\/j.ctrv.2015.09.002_b0145","first-page":"1738","article-title":"Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines","volume":"86","author":"Cassoni","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2015.09.002_b0150","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.regpep.2010.03.011","article-title":"Ghrelin: a potential therapeutic target for cancer","volume":"163","author":"Nikolopoulos","year":"2010","journal-title":"Regul Pept"},{"key":"10.1016\/j.ctrv.2015.09.002_b0155","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.mce.2011.04.013","article-title":"Ghrelin and cancer","volume":"340","author":"Chopin","year":"2011","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.ctrv.2015.09.002_b0160","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1007\/s00520-013-1800-0","article-title":"Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model","volume":"21","author":"Northrup","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ctrv.2015.09.002_b0165","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/sj.cgt.7700767","article-title":"Growth hormone releasing hormone plasmid supplementation, a potential treatment for cancer cachexia, does not increase tumor growth in nude mice","volume":"12","author":"Khan","year":"2005","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.ctrv.2015.09.002_b0170","doi-asserted-by":"crossref","first-page":"6303","DOI":"10.3748\/wjg.14.6303","article-title":"Growth hormone releasing peptide 2 reverses anorexia associated with chemotherapy with 5-fluorouracil in colon cancer cell-bearing mice","volume":"14","author":"Perboni","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ctrv.2015.09.002_b0175","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1093\/toxsci\/kfm059","article-title":"Recombinant rat and mouse growth hormones: risk assessment of carcinogenic potential in 2-year bioassays in rats and mice","volume":"97","author":"Farris","year":"2007","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.ctrv.2015.09.002_b0180","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2007.25.18_suppl.9133","article-title":"A Phase II randomized, placebo controlled, double-blind study of the efficacy and safety of RC-1291 (RC) for the treatment of cancer cachexia","volume":"25","author":"Garcia","year":"2007","journal-title":"J Clin Oncol."},{"issue":"11","key":"10.1016\/j.ctrv.2015.09.002_b0185","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/nrc927","article-title":"Cachexia in cancer patients","volume":"2","author":"Tisdale","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2015.09.002_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2013.08.005","article-title":"Malnutrition, anorexia and cachexia in cancer patients: a mini-review on pathogenesis and treatment","author":"Nicolini","year":"2013","journal-title":"Biomed Pharmacother"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737215001668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737215001668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T07:32:22Z","timestamp":1599550342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737215001668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0305737215001668"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2015.09.002","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms of anorexia\u2013cachexia syndrome and rational for treatment with selective ghrelin receptor agonist","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2015.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}